<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38352659</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-3546</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Brain, behavior, &amp; immunity - health</Title><ISOAbbreviation>Brain Behav Immun Health</ISOAbbreviation></Journal><ArticleTitle>Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19.</ArticleTitle><Pagination><StartPage>100733</StartPage><MedlinePgn>100733</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100733</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbih.2024.100733</ELocationID><Abstract><AbstractText>A subset of patients experiences persistent fatigue symptoms after COVID-19, and patients may develop long COVID, which is characterized by lasting systemic symptoms. No treatments for this condition have been validated and are urgently warranted. In this pilot study, we assessed whether treatment with low-dose naltrexone (LDN, 4.5&#xa0;mg/day) and supplementation with NAD&#xa0;+&#xa0;through iontophoresis patches could improve fatigue symptoms and quality of life in 36 patients with persistent moderate/severe fatigue after COVID-19. We detected a significant increase from baseline in SF-36 survey scores after 12 weeks of treatment (mean total SF-36 score 36.5 [SD: 15.6] vs. 52.1 [24.8]; p&#xa0;&lt;&#xa0;0.0001), suggestive of improvement of quality of life. Furthermore, participants scored significantly lower on the Chalder fatigue scale after 12 weeks of treatment (baseline: 25.9 [4.6], 12 weeks: 17.4 [9.7]; p&#xa0;&lt;&#xa0;0.0001). We found a subset of 52&#xa0;% of patients to be responders after 12 weeks of treatment. Treatment was generally safe, with mild adverse events previously reported for LDN, which could be managed with dose adjustments. The iontophoresis patches were associated with mild, short-lived skin irritation in 25&#xa0;% of patients. Our data suggest treatment with LDN and NAD+ is safe and may be beneficial in a subset of patients with persistent fatigue after COVID-19. Larger randomized controlled trials will have to confirm our data and determine which patient subpopulations might benefit most from this strategy.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Isman</LastName><ForeName>Anar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AgelessRx, 2370 E Stadium Blvd #2049, Ann Arbor, MI, 48104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyquist</LastName><ForeName>Andy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AgelessRx, 2370 E Stadium Blvd #2049, Ann Arbor, MI, 48104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strecker</LastName><ForeName>Bailey</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>AgelessRx, 2370 E Stadium Blvd #2049, Ann Arbor, MI, 48104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harinath</LastName><ForeName>Girish</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AgelessRx, 2370 E Stadium Blvd #2049, Ann Arbor, MI, 48104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>AgelessRx, 2370 E Stadium Blvd #2049, Ann Arbor, MI, 48104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xingyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zalzala</LastName><ForeName>Sajad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AgelessRx, 2370 E Stadium Blvd #2049, Ann Arbor, MI, 48104, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Behav Immun Health</MedlineTA><NlmUniqueID>101759062</NlmUniqueID><ISSNLinking>2666-3546</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Low dose naltrexone</Keyword><Keyword MajorTopicYN="N">NAD+</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">SF-36</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AgelessRx is a longevity-focused telemedicine platform that is the sponsor of several clinical trials, including interventional and observational efforts for use of repurposed gerotherapeutics. AI, AN, BS, GH, VL, SZ are employees of AgelessRx.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>14</Day><Hour>3</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38352659</ArticleId><ArticleId IdType="pmc">PMC10862402</ArticleId><ArticleId IdType="doi">10.1016/j.bbih.2024.100733</ArticleId><ArticleId IdType="pii">S2666-3546(24)00011-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altay O., Arif M., Li X., et al. Combined metabolic Activators Accelerates recovery in mild-to-moderate COVID-19. Adv. Sci. Sep, 2021;8(17) doi: 10.1002/advs.202101222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202101222</ArticleId><ArticleId IdType="pmc">PMC8420376</ArticleId><ArticleId IdType="pubmed">34180141</ArticleId></ArticleIdList></Reference><Reference><Citation>Atchison C.J., Davies B., Cooper E., et al. Long-term health impacts of COVID-19 among 242,712 adults in England. Nat. Commun. Oct 24, 2023;14(1):6588. doi: 10.1038/s41467-023-41879-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41879-2</ArticleId><ArticleId IdType="pmc">PMC10598213</ArticleId><ArticleId IdType="pubmed">37875536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., Olde Hartman T.C., Rosmalen J.G.M., Lifelines Corona Research I. Persistence of somatic symptoms after COVID-19 in The Netherlands: an observational cohort study. Lancet. Aug 6, 2022;400(10350):452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton M.J., Chapman B.P., Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. Jan6, 2020;(1):13. doi: 10.1136/bcr-2019-232502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2019-232502</ArticleId><ArticleId IdType="pmc">PMC6954765</ArticleId><ArticleId IdType="pubmed">31911410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bureau NCfHSUC  Household Pulse survey. Long COVID. Dec, 2023 https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm</Citation></Reference><Reference><Citation>Castro-Marrero J., Segundo M.J., Lacasa M., Martinez-Martinez A., Sentanes R.S., Alegre-Martin J. Effect of Dietary coenzyme Q10 Plus NADH supplementation on fatigue Perception and health-related quality of life in individuals with myalgic encephalomyelitis/chronic fatigue syndrome: a prospective, randomized, Double-Blind, placebo-controlled trial. Nutrients. Jul 30, 2021;(8):13. doi: 10.3390/nu13082658.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13082658</ArticleId><ArticleId IdType="pmc">PMC8399248</ArticleId><ArticleId IdType="pubmed">34444817</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella M., Chalder T. Measuring fatigue in clinical and community settings. J. Psychosom. Res. Jul, 2010;69(1):17&#x2013;22. doi: 10.1016/j.jpsychores.2009.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2009.10.007</ArticleId><ArticleId IdType="pubmed">20630259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J. Infect. Dis. Nov 1, 2022;226(9):1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Choubey A., Dehury B., Kumar S., Medhi B., Mondal P. Naltrexone a potential therapeutic candidate for COVID-19. J. Biomol. Struct. Dyn. Feb, 2022;40(3):963&#x2013;970. doi: 10.1080/07391102.2020.1820379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1820379</ArticleId><ArticleId IdType="pmc">PMC7544934</ArticleId><ArticleId IdType="pubmed">32930058</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. Mar, 2023;21(3):133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding J.L., Oviedo S.A., Ali M.K., et al. The bidirectional association between diabetes and long-COVID-19 - a systematic review. Diabetes Res. Clin. Pract. Jan, 2023;195 doi: 10.1016/j.diabres.2022.110202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2022.110202</ArticleId><ArticleId IdType="pmc">PMC9727969</ArticleId><ArticleId IdType="pubmed">36496030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes V., Morris J., Wolfe C., Morgan M. The SF-36 health survey questionnaire: is it suitable for use with older adults? Age Ageing. Mar, 1995;24(2):120&#x2013;125. doi: 10.1093/ageing/24.2.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/24.2.120</ArticleId><ArticleId IdType="pubmed">7793333</ArticleId></ArticleIdList></Reference><Reference><Citation>Heer C.D., Sanderson D.J., Voth L.S., et al. Coronavirus infection and PARP expression dysregulate the NAD Metabolome: an actionable component of innate immunity. bioRxiv. Oct 6, 2020 doi: 10.1101/2020.04.17.047480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.17.047480</ArticleId><ArticleId IdType="pmc">PMC7834058</ArticleId><ArticleId IdType="pubmed">33051211</ArticleId></ArticleIdList></Reference><Reference><Citation>Horenstein A.L., Faini A.C., Malavasi F. CD38 in the age of COVID-19: a medical perspective. Physiol. Rev. Oct 1, 2021;101(4):1457&#x2013;1486. doi: 10.1152/physrev.00046.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00046.2020</ArticleId><ArticleId IdType="pmc">PMC8313238</ArticleId><ArticleId IdType="pubmed">33787351</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C. The Chalder fatigue scale (CFQ 11) Occup. Med. (Lond.) Jan, 2015;65(1):86. doi: 10.1093/occmed/kqu168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqu168</ArticleId><ArticleId IdType="pubmed">25559796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L.A., Dorri J.A. ME/CFS and post-exertional malaise among patients with long COVID. Neurol. Int. Dec 20, 2022;15(1):1&#x2013;11. doi: 10.3390/neurolint15010001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/neurolint15010001</ArticleId><ArticleId IdType="pmc">PMC9844405</ArticleId><ArticleId IdType="pubmed">36648965</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C., Coulter A., Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. May 29, 1993;306(6890):1437&#x2013;1440. doi: 10.1136/bmj.306.6890.1437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.306.6890.1437</ArticleId><ArticleId IdType="pmc">PMC1677870</ArticleId><ArticleId IdType="pubmed">8518639</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Lipkin W.I. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. Front. Med. 2023;10 doi: 10.3389/fmed.2023.1187163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1187163</ArticleId><ArticleId IdType="pmc">PMC10278546</ArticleId><ArticleId IdType="pubmed">37342500</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., You Y., Griffin N., Feng J., Shan F. Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol. Aug, 2018;61:178&#x2013;184. doi: 10.1016/j.intimp.2018.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.05.020</ArticleId><ArticleId IdType="pubmed">29885638</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchian M.L., Higny J., Benoit M., et al. Unmasking Pandemic Echoes: an in-Depth review of long COVID's Unabated cardiovascular consequences beyond 2020. Diagnostics. Nov2, 2023;(21):13. doi: 10.3390/diagnostics13213368.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13213368</ArticleId><ArticleId IdType="pmc">PMC10647305</ArticleId><ArticleId IdType="pubmed">37958264</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R., Wentzel A.R., Richards G.A. COVID-19: NAD(+) deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity. Med. Hypotheses. Nov, 2020;144 doi: 10.1016/j.mehy.2020.110044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110044</ArticleId><ArticleId IdType="pmc">PMC7322475</ArticleId><ArticleId IdType="pubmed">32758884</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Kelly B., Vidal L., McHugh T., Woo J., Avramovic G., Lambert J.S. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. Oct, 2022;24 doi: 10.1016/j.bbih.2022.100485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney L.L., Routen A., Gillies C., et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. Jan, 2023;55 doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Omran H.M., Almaliki M.S. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: a hypothesis. J Infect Public Health. Sep, 2020;13(9):1196&#x2013;1201. doi: 10.1016/j.jiph.2020.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.06.004</ArticleId><ArticleId IdType="pmc">PMC7275989</ArticleId><ArticleId IdType="pubmed">32534944</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkitny L., Younger J. Reduced pro-inflammatory cytokines after Eight Weeks of low-dose naltrexone for fibromyalgia. Biomedicines. Apr 18, 2017;(2):5. doi: 10.3390/biomedicines5020016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines5020016</ArticleId><ArticleId IdType="pmc">PMC5489802</ArticleId><ArticleId IdType="pubmed">28536359</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten D.K., Schultz B.G., Berlau D.J. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain Disorders. Pharmacotherapy. Mar, 2018;38(3):382&#x2013;389. doi: 10.1002/phar.2086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.2086</ArticleId><ArticleId IdType="pubmed">29377216</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Guevara-Coto J., Yogendra R., et al. Immune-based Prediction of COVID-19 Severity and Chronicity Decoded using Machine Learning. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.700782.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700782</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B., Tate A.M., Gluck D., Rosenson R.S., Goonewardena S.N. Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. Eur Heart J Cardiovasc Pharmacother. Jun 8, 2022;8(4):402&#x2013;405. doi: 10.1093/ehjcvp/pvac014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvac014</ArticleId><ArticleId IdType="pmc">PMC8903502</ArticleId><ArticleId IdType="pubmed">35179184</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo O., Pesonen P., Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Fatigue: Biomedicine, Health &amp; Behavior. 2019/10;7(4):207&#x2013;217. doi: 10.1080/21641846.2019.1692770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2019.1692770</ArticleId></ArticleIdList></Reference><Reference><Citation>Potere N., Batticciotto A., Vecchie A., et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. Jun, 2021;17(6):601&#x2013;618. doi: 10.1080/1744666X.2021.1919086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1919086</ArticleId><ArticleId IdType="pubmed">33874829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultani G., Samsudeen A.F., Osborne B., Turner N. NAD(+) : a key metabolic regulator with great therapeutic potential. J. Neuroendocrinol. Oct, 2017;29(10) doi: 10.1111/jne.12508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jne.12508</ArticleId><ArticleId IdType="pubmed">28718934</ArticleId></ArticleIdList></Reference><Reference><Citation>Toljan K., Vrooman B. Low-dose naltrexone (LDN)-Review of therapeutic Utilization. Med. Sci. Sep 21, 2018;6(4) doi: 10.3390/medsci6040082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci6040082</ArticleId><ArticleId IdType="pmc">PMC6313374</ArticleId><ArticleId IdType="pubmed">30248938</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.T., Porcher R., Pane I., Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat. Commun. Apr 5, 2022;13(1):1812. doi: 10.1038/s41467-022-29513-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29513-z</ArticleId><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Trofimovitch D., Baumrucker S.J. Pharmacology Update: low-dose naltrexone as a possible Nonopioid Modality for some chronic, Nonmalignant pain syndromes. Am J Hosp Palliat Care. Oct, 2019;36(10):907&#x2013;912. doi: 10.1177/1049909119838974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1049909119838974</ArticleId><ArticleId IdType="pubmed">30917675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware J.E., Jr., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. Jun, 1992;30(6):473&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">1593914</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong T.L., Weitzer D.J. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-A systemic review and comparison of clinical presentation and Symptomatology. Medicina (Kaunas) Apr 26, 2021;57(5) doi: 10.3390/medicina57050418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M., Schultz M.B., Sinclair D.A. NAD(+) in COVID-19 and viral infections. Trends Immunol. Apr, 2022;43(4):283&#x2013;295. doi: 10.1016/j.it.2022.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.001</ArticleId><ArticleId IdType="pmc">PMC8831132</ArticleId><ArticleId IdType="pubmed">35221228</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>